vs
Side-by-side financial comparison of Global Business Travel Group, Inc. (GBTG) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Global Business Travel Group, Inc. is the larger business by last-quarter revenue ($792.0M vs $619.8M, roughly 1.3× QuidelOrtho Corp). Global Business Travel Group, Inc. runs the higher net margin — 10.5% vs -14.8%, a 25.3% gap on every dollar of revenue. On growth, Global Business Travel Group, Inc. posted the faster year-over-year revenue change (34.0% vs -10.5%). Over the past eight quarters, Global Business Travel Group, Inc.'s revenue compounded faster (13.9% CAGR vs -6.6%).
A travel management company (TMC) is a travel agency which manages organizations' corporate or business travel programs. Such companies will often provide an end-user online booking tool, mobile application, program management, and consulting teams, executive travel services, meetings and events support, reporting functionality, duty of care, and more. Non-Profit travel management companies also provide services to manage complex visa requirements, pre-trip medical needs, remote area travel, ...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
GBTG vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $619.8M |
| Net Profit | $83.0M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | 3.7% | — |
| Net Margin | 10.5% | -14.8% |
| Revenue YoY | 34.0% | -10.5% |
| Net Profit YoY | 692.9% | — |
| EPS (diluted) | $0.16 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $792.0M | — | ||
| Q3 25 | $674.0M | $699.9M | ||
| Q2 25 | $631.0M | $613.9M | ||
| Q1 25 | $621.0M | $692.8M | ||
| Q4 24 | $591.0M | $707.8M | ||
| Q3 24 | $597.0M | $727.1M | ||
| Q2 24 | $625.0M | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $83.0M | — | ||
| Q3 25 | $-62.0M | $-733.0M | ||
| Q2 25 | $15.0M | $-255.4M | ||
| Q1 25 | $75.0M | $-12.7M | ||
| Q4 24 | $-14.0M | $-178.4M | ||
| Q3 24 | $-128.0M | $-19.9M | ||
| Q2 24 | $27.0M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | — | ||
| Q3 25 | 1.8% | -100.7% | ||
| Q2 25 | 5.4% | -29.4% | ||
| Q1 25 | 8.9% | 4.7% | ||
| Q4 24 | 5.1% | -14.2% | ||
| Q3 24 | 4.5% | 2.1% | ||
| Q2 24 | 6.7% | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | 10.5% | — | ||
| Q3 25 | -9.2% | -104.7% | ||
| Q2 25 | 2.4% | -41.6% | ||
| Q1 25 | 12.1% | -1.8% | ||
| Q4 24 | -2.4% | -25.2% | ||
| Q3 24 | -21.4% | -2.7% | ||
| Q2 24 | 4.3% | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | $0.16 | — | ||
| Q3 25 | $-0.13 | $-10.78 | ||
| Q2 25 | $0.03 | $-3.77 | ||
| Q1 25 | $0.16 | $-0.19 | ||
| Q4 24 | $-0.04 | $-2.54 | ||
| Q3 24 | $-0.28 | $-0.30 | ||
| Q2 24 | $0.06 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $434.0M | $140.4M |
| Total DebtLower is stronger | $1.4B | $2.5B |
| Stockholders' EquityBook value | $1.6B | $1.9B |
| Total Assets | $4.9B | $5.6B |
| Debt / EquityLower = less leverage | 0.88× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $434.0M | — | ||
| Q3 25 | $427.0M | $98.1M | ||
| Q2 25 | $601.0M | $151.7M | ||
| Q1 25 | $552.0M | $127.1M | ||
| Q4 24 | $536.0M | $98.3M | ||
| Q3 24 | $524.0M | $143.7M | ||
| Q2 24 | $515.0M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $2.5B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.4B | $2.1B | ||
| Q4 24 | $1.4B | $2.1B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | $2.0B | ||
| Q2 25 | $1.2B | $2.8B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.1B | $3.0B | ||
| Q3 24 | $1.1B | $3.2B | ||
| Q2 24 | $1.2B | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $4.9B | — | ||
| Q3 25 | $4.8B | $5.7B | ||
| Q2 25 | $3.9B | $6.4B | ||
| Q1 25 | $3.8B | $6.5B | ||
| Q4 24 | $3.6B | $6.4B | ||
| Q3 24 | $3.8B | $6.8B | ||
| Q2 24 | $3.8B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 0.88× | — | ||
| Q3 25 | 0.91× | 1.23× | ||
| Q2 25 | 1.15× | 0.74× | ||
| Q1 25 | 1.23× | 0.70× | ||
| Q4 24 | 1.32× | 0.72× | ||
| Q3 24 | 1.26× | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $52.0M | — |
| Free Cash FlowOCF − Capex | $13.0M | — |
| FCF MarginFCF / Revenue | 1.6% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | 0.63× | — |
| TTM Free Cash FlowTrailing 4 quarters | $104.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $52.0M | — | ||
| Q3 25 | $71.0M | $-45.5M | ||
| Q2 25 | $57.0M | $-46.8M | ||
| Q1 25 | $53.0M | $65.6M | ||
| Q4 24 | $65.0M | $63.7M | ||
| Q3 24 | $85.0M | $117.9M | ||
| Q2 24 | $73.0M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $13.0M | — | ||
| Q3 25 | $38.0M | $-94.7M | ||
| Q2 25 | $27.0M | $-84.3M | ||
| Q1 25 | $26.0M | $9.4M | ||
| Q4 24 | $33.0M | $16.5M | ||
| Q3 24 | $59.0M | $71.4M | ||
| Q2 24 | $49.0M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | 5.6% | -13.5% | ||
| Q2 25 | 4.3% | -13.7% | ||
| Q1 25 | 4.2% | 1.4% | ||
| Q4 24 | 5.6% | 2.3% | ||
| Q3 24 | 9.9% | 9.8% | ||
| Q2 24 | 7.8% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.9% | 7.0% | ||
| Q2 25 | 4.8% | 6.1% | ||
| Q1 25 | 4.3% | 8.1% | ||
| Q4 24 | 5.4% | 6.7% | ||
| Q3 24 | 4.4% | 6.4% | ||
| Q2 24 | 3.8% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.63× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.80× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GBTG
| Travel | $620.0M | 78% |
| Other | $172.0M | 22% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
